An International Publisher for Academic and Scientific Journals
Author Login
Scholars Journal of Medical Case Reports | Volume-13 | Issue-10
What About Autologous Stem-Cell Transplantation in Primary Central Nervous System Lymphoma?
W.S. Ouedraogo, M.A. Aznag, M. Hamidine, K.O. Josias, S. Achouch, A. Raissi
Published: Oct. 6, 2025 |
47
29
Pages: 2195-2198
Downloads
Abstract
Autologous hematopoietic stem-cell transplantation (ASCT) as consolidation after high-dose methotrexate (HD-MTX)-based induction chemotherapy has emerged as an effective strategy for achieving durable remissions while reducing the need for whole-brain radiotherapy (WBRT) and its associated neurotoxicity risks, according to meta-analyses, randomized trials, and systematic reviews [1,2,13,3]. In younger, eligible patients, randomized studies report comparable efficacy between WBRT and high-dose chemotherapy followed by ASCT, but with superior neurocognitive tolerance after ASCT supporting its preferential use as consolidation in selected patients [2,13].